AbstractMusculoskeletal infections represent a significant proportion of clinical workload for infectious diseases (ID) providers, often presenting complex diagnostic and therapeutic challenges. Many providers may feel inadequately prepared to manage these conditions, which require a nuanced understanding of microbiology, musculoskeletal anatomy, surgical intervention, and orthopedic hardware. We implemented a pair of educational interventions including an online library of high-yield musculoskeletal ID literature and an educational podcast.

Although the characteristics of complicated candidaemia are well known, uncomplicated disease remains undefined. Recommended treatment duration for candidaemia is 14 days after bloodstream infection i...

The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address ...

AbstractImplanted biomedical devices are becoming ubiquitous in the practice of medicine but are at risk for biofilm-related infection. The biomaterial composition of these devices can significantly affect their risk for infection. Biomaterials design is complex with compositional choices leading to different properties, including mechanical strength, biodegradation rate, and ability to locally release therapeutics. In this review, we introduce the field of “Implant Infectious Diseases,” review practical biomaterial fundamentals for the infectious disease (ID) clinician, and apply these principles to case vignettes. This review serves as a primer for a broad ID audience to better understand the role of biomaterials in medical devices and as therapeutics.

Examine how extreme weather events, air pollution, and rising temperatures are contributing to the changing epidemiology and distribution of infectious eye diseases.

A tool that connects everyday work into one space. It gives you and your teams AI tools—search, writing, note-taking—inside an all-in-one, flexible workspace.

Abstract. Clinicians are constantly bombarded with an onslaught of newly published data, yet they must make clinical decisions despite a dearth of clinical

As Infectious Diseases physicians, when asked about the importance of antimicrobial stewardship, many of us may share the same answers. For one, if we continue our current practices, antimicrobial resistance will lead to more deaths by the year 2050 than cancer [1]. Further, there are the risks of diarrhea, Clostridioides difficile colitis, cytopenia, hepatotoxicity, nephrotoxicity, severe drug eruption, among additional complications. Although these answers are alarming and motivate many of us in infectious diseases to appropriately prescribe antimicrobials, I find myself troubled when it does not persuade others of the importance of stewardship. For many physicians, prescribing antibiotics provides security in situations of uncertainty, rationalized by the familiar mantra, “just in case.” Because “cytopenia and hepatoxicity can be monitored with labs,” “C. difficile is treatable,” and “why worry about resistance decades later, when I have a patient to worry about now.” Shifting these mindsets is challenging, and I realized during fellowship that strategic communication, negotiation, and persuasion were just as important to my performance as an Infectious Diseases fellow as was my expertise in clinical guidelines. However, as I transitioned to the bench for my physician scientist training, I came to appreciate a better, more convincing answer for the importance of antimicrobial stewardship. An answer that I believe validates the need for our specialty and makes me look at the future of our field with nothing but optimism. It centers on the importance of microbes.

AbstractCases of Candida infection have been on the rise in recent years. A comprehensive and clear understanding of the mechanisms of antifungal resistance is fundamental for developing novel therapies to address the current and emerging threat of fungal diseases. Certain Candida species can cause superficial or invasive infections in immunocompromised hosts, and invasive Candida infections are major contributors to infectious disease deaths. As fungi are eukaryotes like humans, there are only a limited number of unique molecular targets available for antifungal drug development. Until recently, there have only been four primary classes of antifungals used to treat systemic fungal infections. Among these, azole antifungals are globally used because they are both inexpensive and effective. Due to various factors, resistance to antifungal drugs—especially azole antifungals—has developed in many Candida species, posing a significant public health threat. This review discusses the known mechanisms of azole antifungal resistance in Candida albicans, Candida auris, Nakaseomyces glabrata, Candida tropicalis, Candida parapsilosis and explores strategies to overcome the resistance problem.